Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis (BOPSAC)

This study has been terminated.
(Not enough patients with the specified criteria could not)
Information provided by (Responsible Party):
Daniel Doberer, Medical University of Vienna Identifier:
First received: June 22, 2009
Last updated: September 14, 2016
Last verified: September 2016

Progressive pulmonary sarcoidosis occurs in up to twenty percent of patients who require persistent treatment, but available treatment options have shown considerable long-term toxicity and uncertain or unproven efficacy. In these patients, pulmonary fibrosis and pulmonary hypertension are common complications which have major prognostic impact. Endothelin-1 (ET-1) has been demonstrated to play a key role in pulmonary fibrosis and pulmonary hypertension, and a potential role in pulmonary sarcoidosis. ET-1 is a potent vasoconstrictor and can promote fibrosis, cell proliferation, and remodeling, and is pro-inflammatory. Preliminary data have shown the therapeutic potential of the endothelin receptor antagonist (ERA) bosentan in sarcoidosis associated pulmonary hypertension.

In this light, the therapeutic potential of bosentan as an add-on treatment in progressive pulmonary sarcoidosis needs to be evaluated.

Condition Intervention Phase
Pulmonary Hypertension
Drug: bosentan
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis

Resource links provided by NLM:

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Treatment efficacy is assessed by a composite clinical score, including six parameters: Pulmonary function test (FVC and DLCO), Blood gas analysis (AaDO2), HRCT (Oberstein score), 6 minute walk test (6-MWD), Dyspnoea (ATS dyspnea scale) [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Assess safety and tolerability of bosentan in progressive pulmonary sarcoidosis [ Time Frame: 6 months ]
  • To evaluate the efficacy of bosentan treatment in the subgroups of patents with and without sarcoidosis-associated pulmonary hypertension. [ Time Frame: 6 months ]

Enrollment: 32
Study Start Date: April 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
placebo b.i.d.
Drug: placebo
identical preparation as the study drug, but without the active substance, administered b.i.d.
Experimental: Bosentan
62.5 mg/125 mg bosentan b.i.d.
Drug: bosentan
62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure.
  • Male and female patients aged > 18 and < 70 years.
  • Histologically proven sarcoidosis diagnosed at least one year before screening.
  • Diagnosis of sarcoidosis and with evidence of pulmonary parenchymal disease on chest X-ray or CT (radiological stage II, III) with or without pulmonary hypertension. Subjects with concurrent extrapulmonary sarcoidosis are encouraged to be enrolled.
  • Progressive disease, defined as follows:

    • Deterioration in the 3-12 month period prior to screening in at least two of the following criteria:

      • increase in clinical symptoms (cough, shortness of breath, chest pain, fatigue or hemoptysis).
      • lung function: decrease of 10% in TLC, FVC or DLCO.
      • worsening of radiographic opacities.
    • Have been receiving pre-study treatment with prednisolone (or equivalent dose of corticosteroid) as a single agent (≥ 10 mg/day) or other immunosuppressants (methotrexate, azathioprine, cyclophosphamide, TNF inhibitors, etc.) within the 3-month period immediately prior to screening. Patients must be on a stable dose of these medications for > 4 weeks before starting the study medication.
  • AST and ALT values within three times upper limit of normal.
  • Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.
  • Negative pregnancy test in female patients.
  • Adequate contraception in female patients of childbearing age.

Exclusion Criteria:

  • Known hypersensitivity to any excipients of the drug formulation or to bosentan.
  • Treatment with another investigational drug within 3 months prior to screening.
  • Pulmonary sarcoidosis:

    • without disease progression as defined above
    • with radiological stage I
    • with radiological stage IV (pulmonary fibrosis with evidence of honey-combing, hilar retraction, bullae and cysts)
  • Other cause of pulmonary disease:

    • Active tuberculosis (or positive Quantiferon test), fungi infection, lymphoma.
    • Chronic obstructive pulmonary disease, asthma, interstitial lung disease other than sarcoid-related
  • Anamnesis of beryllium or asbestos exposition
  • Previous smoking (> 10 PY), or active smoker
  • Previous administration of bosentan
  • Positive results from the hepatitis serology, except for vaccinated subjects, at screening.
  • Positive results from the HIV serology at screening.
  • Malignancy requiring chemotherapy or radiation
  • Uncontrolled other disease like

    • Chronic heart failure (NYHA III, IV)
    • Diabetes mellitus (blood glucose 2x per day > 250 mg/dl , HbA1c > 10 %)
    • Arterial hypertension (SBP > 180 mmHg)
  • Concomitant treatment with cyclosporine A
  • Concomitant treatment with tacrolimus or sirolimus
  • Concomitant treatment with glibenclamide
  • Are pregnant, nursing, or planning pregnancy during the trial or within six month period thereafter.
  • Have a known substance dependency (drug or alcohol within 3 years of screening).
  • Presumed non-compliance.
  • Legal incapacity or limited legal capacity at screening.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00926627

General Hospital Vienna
Vienna, Austria, 1090
Wilhelminenspital Wien
Vienna, Austria, 1180
Sponsors and Collaborators
Daniel Doberer
Study Director: Daniel Doberer, MD, MSc Medical University of Vienna
  More Information

Additional Information:
Responsible Party: Daniel Doberer, Research Associate, Medical University of Vienna Identifier: NCT00926627     History of Changes
Other Study ID Numbers: EudraCT - 2007-005117-18
Study First Received: June 22, 2009
Last Updated: September 14, 2016

Keywords provided by Medical University of Vienna:
endothelin receptor antagonist

Additional relevant MeSH terms:
Hypertension, Pulmonary
Sarcoidosis, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Lung Diseases, Interstitial
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on April 28, 2017